p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism

Cancer Research

Volumn 64, Issue 6, 2004, Pages 1951-1958

  Gurova, Katerina V ^a   Hill, Jason E ^a,b   Razorenova, Olga V ^a   Chumakov, Peter M ^a   Gudkov, Andrei V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; LENTIVIRUS VECTOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL FUSION; CELL NUCLEUS; CONTROLLED STUDY; EMBRYO; GENE MUTATION; GENE REPRESSION; GENETIC TRANSDUCTION; GENOTOXICITY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

CARCINOMA, RENAL CELL; CELL FUSION; CELL NUCLEUS; DNA DAMAGE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; HYBRID CELLS; KIDNEY; KIDNEY NEOPLASMS; LENTIVIRUS; LUCIFERASES; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETROVIRIDAE; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1542615083     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1541     Document Type: Article

References (32)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA-Cancer J Clin 1999;49:8-31.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31.
3. Bast R, Kufe D, Pollock R, Weichselbaum R, Holland J, Frei E. Cancer medicine, 5th ed. Hamilton, Ontario, Canada: B. C. Decker, 2000.
4. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995;7:547-53.
5. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999;55:64-75.
6. Soussi T, Dehouche K, Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 2000;15:105-13.
7. IARC p53 Database. www.IARC.fr/p53/index.html.
8. Tomasino RM, Morello V, Tralongo V, et al. p53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization. Pathologica 1994;86:227-33.
9. Bui MH, Zisman A, Pantuck AJ, et al. Prognostic factors and molecular markers for renal cell carcinoma. Exp Rev Anticancer Ther 2001;1:565-75.
10. Hofmockel G, Wittmann A, Dammrich J, Bassukas ID. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res 1996;16:3807-11.
11. Sejima T, Miyagawa I. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma. Eur Urol 1999;35:242-8.
12. Gelb AB. Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (Phila.) 1997;80:981-6.
13. Picksley SM, Spicer JF, Barnes DM, Lane DP. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Acta Oncol 1996;35:429-34.
14. Oren M, Damalas A, Gottlieb T, et al. Regulation of p53: intricate loops and delicate balances Biochem Pharmacol 2002;64:865-71.
15. Riemenschneider MJ, Buschges R, Wolter M, et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 1999;59:6091-6.
16. Tannapfel A, Busse C, Weinans L, et al. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 2001;20:7104-9.
17. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
18. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999;18:7690-700.
19. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science (Wash. DC) 2002;296:550-3.
20. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992;12:2866-71.
21. Chen JY, Funk WD, Wright WE, Shay JW, Minna JD. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 1993;8:2159-66.
22. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
23. Kichina J, Rauth S, Das Gupta T, Gudkov AV. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. Oncogene 2003;22:4911-7.
24. Chernov MV, Stark GR. The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Oncogene 1997;14:2503-10.
25. Zeremski M, Hill JE, Kwek SS, et al. Structure and regulation of the mouse ing1 gene. Three alternative transcripts encode two phd finger proteins that have opposite effects on p53 function. J Biol Chem 1999;274:32172-81.
26. Ossovskaya VS, Mazo IA, Chernov MV, et al. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci USA 1996;93:10309-14.
27. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999;246:280-9.
28. Moll UM, LaQuaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995;92:4407-11.
29. el-Deiry WS, Kem SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992;1:45-9.
30. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
31. Kawada Y, Nakamura M, Ishida E, et al. Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas. Jpn J Cancer Res 2001;92:1293-9.
32. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003;112:29-40.